The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
A comparison of the biological activities of wild‐type and mutant p53
Abstract
Tumorigenesis is characterized by a series of genetic alterations in both dominant oncogenes and tumor suppressor genes. A hallmark of tumor suppressor genes is that both alleles are generally altered during transformation, which usually represents a loss of function phenotype. The p53 tumor suppressor gene is the most frequently affected gene detected in human cancer. There is now growing evidence suggesting that mutation of p53 may involve not only a loss of function of wild‐type p53 activity but also a gain of function phenotype contributed by the mutant p53 protein. The study of the biological properties and functions of both wild‐type and mutant p53 is central to our understanding of human cancer. These properties and functions of wild‐type and mutant p53 will be compared and contrasted here and elsewhere within this thematic issue. In addition, the mechanisms of inactivation of p53 function, which include: 1 ) mutation, 2 ) inhibition by viral oncogene products, 3 ) inhibition by cellular regulators, and 4 ) alteration in subcellular localization, will be discussed.—Zambetti, G. P., Levine, A. J. A comparison of the biological activities of wild‐type and mutant p53. FASEB J. 7: 855‐865; 1993.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Self-citationGerm Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 3×
“Consistent with this hypothesis, transient transfection experiments demonstrated that expression of the MDM-2 gene inhibited the transactivation of a p53 responsive minimal promoter-CAT reporter gene by wild-type p53 (90).”
BackgroundInfluentialSelf-citationKastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Self-citationThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Self-citationDefinition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., & Kastan, M. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7491 · Cited by 1,837
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
Self-citationSuppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
Mutational hot spot in the p53 gene in human hepatocellular carcinomas
Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., & Harris, C. C. (1991) · Nature · doi:10.1038/350427a0 · Cited by 1,534
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome?
LI, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,509
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
Bressac, B., Kew, M., Wands, J., & Ozturk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,432
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., & Tlsty, T. D. (1992) · Cell · doi:10.1016/0092-8674(92)90243-6 · Cited by 1,332
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,211
Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., & Levine, A. J. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.531 · Cited by 1,144
Self-citationYin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., & Wahl, G. M. (1992) · Cell · doi:10.1016/0092-8674(92)90244-7 · Cited by 1,089
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Increased expression of mutant forms of p53 oncogene in primary lung cancer
Iggo, R., Bartek, J., Lane, D., Gatter, K., Harris, A. L., & Bartek, J. (1990) · The Lancet · doi:10.1016/0140-6736(90)90801-b · Cited by 1,031
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Regulation of the specific DNA binding function of p53
Hupp, T. R., Meek, D. W., Midgley, C. A., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 909
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Self-citationUV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893
Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.
Debbas, M., & White, E. (1993) · Genes & Development · doi:10.1101/gad.7.4.546 · Cited by 871
Sarnow, P., Ho, Y. S., Williams, J., & Levine, A. J. (1982) · Cell · doi:10.1016/0092-8674(82)90356-7 · Cited by 836
Self-citationPresence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
p53 functions as a cell cycle control protein in osteosarcomas.
Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., & Vogelstein, B. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5772 · Cited by 772
Michalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769
A transcriptionally active DNA-binding site for human p53 protein complexes.
Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., & Shay, J. W. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.6.2866 · Cited by 732
Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
Chin, K.-V., Ueda, K., Pastan, I., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726
Fakharzadeh, S. S., Trusko, S. P., & George, D. L. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07676.x · Cited by 704
Wild-type p53 can inhibit oncogene-mediated focus formation.
Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., & Oren, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8763 · Cited by 692
Gannon, J. V., Greaves, R., Iggo, R., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 688
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bártek, J., Iggo, R. D., Gannon, J., & Lane, D. P. (1990) · PubMed · Cited by 658
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 619
Milner, J., & Medcalf, E. A. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612
Wild-type p53 activates transcription in vitro
Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C. (1992) · Nature · doi:10.1038/358083a0 · Cited by 579 · cited 2×
“Purified human and murine wild-type p53 protein can in fact strongly transactivate transcription from a minimal human fos promoter that contains a single 33 bp RGC p53 DNA binding element upstream from the TATA element in an in vitro transcription assay using partially purified HeLa cell nuclear extracts (78).”
BackgroundMethodHinds, P., Finlay, C., & Levine, A. J. (1989) · Journal of Virology · doi:10.1128/jvi.63.2.739-746.1989 · Cited by 577
Self-citationTwo distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
Moll, U. M., Riou, G., & Levine, A. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7262 · Cited by 575
Self-citationCellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53
Jenkins, J. R., Rudge, K., & Currie, G. A. (1984) · Nature · doi:10.1038/312651a0 · Cited by 552
Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.
Martinez, J., Georgoff, I., Martinez, J., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.2.151 · Cited by 527
Self-citationGenetic Mechanisms of Tumor Suppression by the Human p53 Gene
Chen, P.-L., Chen, Y., Bookstein, R., & Lee, W.-H. (1990) · Science · doi:10.1126/science.2274789 · Cited by 518
Wild-type p53 binds to the TATA-binding protein and represses transcription.
Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J., & Shenk, T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12028 · Cited by 504
Self-citationGrowth regulation of a cellular tumour antigen, p53, in nontransformed cells
Reich, N. C., & Levine, A. J. (1984) · Nature · doi:10.1038/308199a0 · Cited by 494
Self-citationHarvey, D. M., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.12b.2375 · Cited by 453
Self-citationWild-type p53 can down-modulate the activity of various promoters.
Ginsberg, D., Mechta, F., Yaniv, M., & Oren, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.9979 · Cited by 435
Malkin, D., Jolly, K. W., Barbier, N., Look, A. T., Friend, S. H., Gebhardt, M. C., Andersen, T. I., Børresen, A.-L., Li, F. P., Garber, J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262002 · Cited by 379
Santhanam, U., Ray, A., & Sehgal, P. B. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7605 · Cited by 375
Bargonetti, J., Friedman, P. N., Kern, S. E., Vogelstein, B., & Prives, C. (1991) · Cell · doi:10.1016/0092-8674(91)90560-l · Cited by 367
Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., & Rotter, V (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565 · Cited by 356
Cahilly-Snyder, L., Yang-Feng, T., Francke, U., & George, D. L. (1987) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01535205 · Cited by 355
Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.
Bischoff, J. R., Friedman, P. N., Marshak, D. R., Prives, C., & Beach, D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4766 · Cited by 342
Vogelstein, B. (1990) · Nature · doi:10.1038/348681a0 · Cited by 324
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301 · Cited by 311 · cited 1×
“p53-mediated suppression of transformed cell growth (93).”
Zambetti, G. P., Bargonetti, J., Walker, K., Prives, C., & Levine, A. J. (1992) · Genes & Development · doi:10.1101/gad.6.7.1143 · Cited by 311
Self-citationPrevalence and Spectrum of Germline Mutations of the p53 Gene among Patients with Sarcoma
Toguchida, J., Yamaguchi, T., Dayton, S. H., Beaughamp, R. L., Herrera, G. E., Ishizaki, K., Yamamuro, T., Meyers, P. A., Little, J. B., Sasaki, M. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262001 · Cited by 307
Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene.
Matlashewski, G., Lamb, P., Pim, D., Peacock, J., Crawford, L., & Benchimol, S. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02287.x · Cited by 299
Lechner, M. S., Mack, D. H., Finicle, A. B., Crook, T., Vousden, K. H., & Laimins, L. A. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05375.x · Cited by 273
Unger, T., Nau, M. M., Segal, S., & Minna, J. D. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05183.x · Cited by 261
Mercer, W. E., Shields, M. T., Lin, D., Appella, E., & Ullrich, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.5.1958 · Cited by 249
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.
Milner, J., Medcalf, E. A., & Cook, A. C. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.12 · Cited by 243
Bargonetti, J., Reynisdóttir, I., Friedman, P. N., & Prives, C. (1992) · Genes & Development · doi:10.1101/gad.6.10.1886 · Cited by 223
Abnormal expression of wild type p53 protein in normal cells of a cancer family patient
Barnes, D. M., Gillett, C. E., Bobrow, L. G., Hanby, A. M., Mohammed, S., Hodgson, S., Leigh, I. M., Purkis, T., MacGeoch, C., Spurr, N. K., et al. (1992) · The Lancet · doi:10.1016/0140-6736(92)92354-i · Cited by 190
Inhibition of viral and cellular promoters by human wild-type p53
Subler, M. A., Martin, D. W., & Deb, S. (1992) · Journal of Virology · doi:10.1128/jvi.66.8.4757-4762.1992 · Cited by 171
Mutant p53 proteins bind DNA abnormally in vitro.
Kern, S. E., Kinzler, K. W., Baker, S. J., Nigro, J. M., Rotter, V., Levine, A. J., Friedman, P. N., Prives, C. L., & Vogelstein, B. (1991) · PubMed · Cited by 163
Self-citationModulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells
Deb, S., Jackson, C. T., Subler, M. A., & Martin, D. W. (1992) · Journal of Virology · doi:10.1128/jvi.66.10.6164-6170.1992 · Cited by 160
The MCK enhancer contains a p53 responsive element.
Weintraub, H., Hauschka, S., & Tapscott, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4570 · Cited by 159
p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis.
Hw, S., Maimets, T., Chumakov, P. M., Brain, R., Addison, C. M., Simanis, V., Rudge, K., Philp, R. J., Grimaldi, M., & Court, W. J. (1990) · PubMed · Cited by 155
Immortalization of rat embryo fibroblasts by the cellular p53 oncogene.
Rovinski, B., & Benchimol, S. (1988) · PubMed · Cited by 153
Oligomerization of oncoprotein p53
Kraiss, S., Quaiser, A., Oren, M., & Montenarh, M. (1988) · Journal of Virology · doi:10.1128/jvi.62.12.4737-4744.1988 · Cited by 147
Ginsberg, D., Michael, D., Ginsberg, D., & Oren, M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.582 · Cited by 142
Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
Shaulsky, G., Goldfinger, N., & Rotter, V. (1991) · PubMed · Cited by 132
Precise epitope mapping of the murine transformation‐associated protein, p53.
Wade-Evans, A. M., & Jenkins, J. R. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03686.x · Cited by 128
A potential transcriptional activation element in the p53 protein.
O’Rourke, R. W., Cw, M., Kato, G. J., Simon, K. J., Dl, C., Dang, C. V., & Hp, K. (1990) · PubMed · Cited by 128
Analysis of p53 Mutants for Transcriptional Activity
Raycroft, L., Schmidt, J. R., Yoas, K., Hao, M., & Lozano, G. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.12.6067 · Cited by 113
Formation of stable p53 homotetramers and multiples of tetramers
Stenger, J. E., Mayr, G. A., Mann, K., & Tegtmeyer, P. (1992) · Molecular Carcinogenesis · doi:10.1002/mc.2940050204 · Cited by 104
The amino acid sequence of murine p53 determined from a c-DNA clone
Pennica, D., Goeddel, D. V., Hayflick, J. S., Reich, N. C., Anderson, C. W., & Levine, A. J. (1984) · Virology · doi:10.1016/0042-6822(84)90316-7 · Cited by 98
Self-citationDNA binding properties of murine p53.
Steinmeyer, K., & Deppert, W. (1988) · PubMed · Cited by 96
Repression of the basal c-fos promoter by wild-type p53
Kley, N., Chung, R. Y., Fay, S., Loeffler, J., & Seizinger, B. R. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.15.4083 · Cited by 90
p53 is associated with p34cdc2 in transformed cells.
Milner, J., Cook, A., & Mason, J. M. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07478.x · Cited by 78
Milner, J., Cook, A., & Sheldon, M. J. (1987) · PubMed · Cited by 78
Energy requirement for degradation of tumor-associated protein p53.
Gronostajski, R. M., Goldberg, A. L., & Pardee, A. B. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.3.442 · Cited by 73
Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma.
Iavarone, A., Matthay, K. K., Steinkirchner, T., & Israel, M. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.4207 · Cited by 71
Wolf, D., Admon, S., Oren, M., & Rotter, V. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.3.552 · Cited by 63
Zambetti, G. P., Olson, D., Labow, M., & Levine, A. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3952 · Cited by 61
Self-citationMammalian p53 can function as a transcription factor in yeast
Iggo, R. D., & Schärer, E. (1992) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(92)90407-y · Cited by 37
(1992) · PubMed
Cited by
Oral and maxillofacial pathology
(1996) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(96)90514-5 · Cited by 2,967
Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,085
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,637
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
Metadata
- Authors
- Zambetti, G. P., & Levine, A. J.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 1993-07
- Volume
- 7
- Issue
- 10
- Pages
- 855-865
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1674633125
- Cited by
- 413
- References
- 93
- FWCI
- 24.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.